Bright Health Gr Analyst Ratings
Bright Health Gr Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 14.86% | RBC Capital | $13 → $16 | Maintains | Sector Perform |
| 06/30/2023 | 510.19% | Nephron Research | → $85 | Upgrades | Hold → Buy |
| 06/15/2023 | -42.57% | Barclays | $4 → $8 | Downgrades | Overweight → Underweight |
| 05/30/2023 | -6.68% | RBC Capital | $80 → $13 | Maintains | Sector Perform |
| 05/23/2023 | 1048.6% | Morgan Stanley | $12800 → $160 | Maintains | Underweight |
| 05/22/2023 | 91788.01% | Morgan Stanley | $160 → $12800 | Maintains | Underweight |
| 05/19/2023 | 1048.6% | Morgan Stanley | $2 → $160 | Maintains | Underweight |
| 12/13/2022 | -96.41% | Goldman Sachs | → $0.5 | Downgrades | Neutral → Sell |
| 11/16/2022 | -91.39% | Citigroup | $2.25 → $1.2 | Maintains | Neutral |
| 10/11/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 08/11/2022 | -78.46% | Piper Sandler | $5 → $3 | Maintains | Overweight |
| 05/12/2022 | -78.46% | Goldman Sachs | $3.5 → $3 | Maintains | Neutral |
| 03/29/2022 | -85.64% | JP Morgan | → $2 | Downgrades | Overweight → Neutral |
| 03/04/2022 | -78.46% | RBC Capital | $9 → $3 | Downgrades | Outperform → Sector Perform |
| 03/03/2022 | -85.64% | Morgan Stanley | $4 → $2 | Maintains | Underweight |
| 03/03/2022 | -74.87% | Goldman Sachs | $5 → $3.5 | Maintains | Neutral |
| 03/03/2022 | -71.28% | Barclays | $5.5 → $4 | Maintains | Overweight |
| 03/03/2022 | -64.11% | Piper Sandler | $10 → $5 | Maintains | Overweight |
| 01/07/2022 | -60.52% | Barclays | $9 → $5.5 | Maintains | Overweight |
| 12/17/2021 | -71.28% | Morgan Stanley | $5 → $4 | Downgrades | Equal-Weight → Underweight |
| 12/16/2021 | -71.28% | Morgan Stanley | $5 → $4 | Downgrades | Equal-Weight → Underweight |
| 12/14/2021 | -64.11% | Goldman Sachs | → $5 | Initiates Coverage On | → Neutral |
| 12/10/2021 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 11/12/2021 | -64.11% | Morgan Stanley | $13 → $5 | Downgrades | Overweight → Equal-Weight |
| 11/10/2021 | -13.85% | Barclays | $17 → $12 | Maintains | Overweight |
| 11/02/2021 | -35.39% | Cowen & Co. | $14 → $9 | Downgrades | Outperform → Market Perform |
| 09/10/2021 | 0.5% | Cowen & Co. | → $14 | Initiates Coverage On | → Outperform |
| 08/31/2021 | -6.68% | Morgan Stanley | $12 → $13 | Maintains | Overweight |
| 08/05/2021 | -13.85% | Morgan Stanley | $18 → $12 | Upgrades | Equal-Weight → Overweight |
| 08/04/2021 | -13.85% | Citigroup | $16 → $12 | Upgrades | Neutral → Buy |
| 07/19/2021 | 29.22% | Morgan Stanley | → $18 | Initiates Coverage On | → Equal-Weight |
| 07/19/2021 | 36.4% | JP Morgan | → $19 | Initiates Coverage On | → Neutral |
| 07/19/2021 | 7.68% | Wolfe Research | → $15 | Initiates Coverage On | → Peer Perform |
| 07/19/2021 | 158.44% | Goldman Sachs | → $36 | Initiates Coverage On | → Buy |
| 07/19/2021 | 57.93% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 07/19/2021 | 14.86% | Citigroup | → $16 | Initiates Coverage On | → Neutral |
| 07/19/2021 | 72.29% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月14日 | 14.86% | 加拿大皇家银行资本 | $13→$16 | 维护 | 行业表现 |
| 2023/06/30 | 510.19% | 肾单位研究 | →$85 | 升级 | 持有→购买 |
| 2023/06/15 | -42.57% | 巴克莱 | $4→$8 | 评级下调 | 增持→减持 |
| 2023年05月30日 | -6.68% | 加拿大皇家银行资本 | $80→$13 | 维护 | 行业表现 |
| 2023年05月23日 | 1048.6% | 摩根士丹利 | $12800→$160 | 维护 | 体重不足 |
| 2023年05月22日 | 91788.01% | 摩根士丹利 | $160→$12800 | 维护 | 体重不足 |
| 2023年05月19日 | 1048.6% | 摩根士丹利 | $2→$160 | 维护 | 体重不足 |
| 2022年12月13日 | -96.41% | 高盛 | →$0.5 | 评级下调 | 中性→销售 |
| 2022年11月16日 | -91.39% | 花旗集团 | $2.25→$1.2 | 维护 | 中性 |
| 2022年10月11日 | - | 摩根大通 | 评级下调 | 中性→减持 | |
| 2022年08月11日 | -78.46% | 派珀·桑德勒 | $5→$3 | 维护 | 超重 |
| 2022年05月12日 | -78.46% | 高盛 | $3.5→$3 | 维护 | 中性 |
| 03/29/2022 | -85.64% | 摩根大通 | →$2 | 评级下调 | 超重→中性 |
| 03/04/2022 | -78.46% | 加拿大皇家银行资本 | $9→$3 | 评级下调 | 跑赢→板块表现 |
| 03/03/2022 | -85.64% | 摩根士丹利 | $4→$2 | 维护 | 体重不足 |
| 03/03/2022 | -74.87% | 高盛 | $5→$3.5 | 维护 | 中性 |
| 03/03/2022 | -71.28% | 巴克莱 | $5.5→$4 | 维护 | 超重 |
| 03/03/2022 | -64.11% | 派珀·桑德勒 | $10→$5 | 维护 | 超重 |
| 01/07/2022 | -60.52% | 巴克莱 | $9→$5.5 | 维护 | 超重 |
| 2021/12/17 | -71.28% | 摩根士丹利 | $5→$4 | 评级下调 | 等重→减码 |
| 12/16/2021 | -71.28% | 摩根士丹利 | $5→$4 | 评级下调 | 等重→减码 |
| 2021年12月14日 | -64.11% | 高盛 | →$5 | 开始承保 | →中性 |
| 2021年12月10日 | - | 摩根大通 | 升级 | 中性→超重 | |
| 2021年11月12日 | -64.11% | 摩根士丹利 | $13→$5 | 评级下调 | 超重→等重 |
| 2021年11月10日 | -13.85% | 巴克莱 | $17→$12 | 维护 | 超重 |
| 11/02/2021 | -35.39% | 考恩公司 | $14→$9 | 评级下调 | 跑赢→市场表现 |
| 09/10/2021 | 百分之零点五 | 考恩公司 | →$14 | 开始承保 | →跑赢大盘 |
| 2021/08/31 | -6.68% | 摩根士丹利 | $12→$13 | 维护 | 超重 |
| 08/05/2021 | -13.85% | 摩根士丹利 | $18→$12 | 升级 | 等重→超重 |
| 08/04/2021 | -13.85% | 花旗集团 | $16→$12 | 升级 | 中性→购买 |
| 07/19/2021 | 29.22% | 摩根士丹利 | →$18 | 开始承保 | →等重 |
| 07/19/2021 | 36.4% | 摩根大通 | →$19 | 开始承保 | →中性 |
| 07/19/2021 | 7.68% | 沃尔夫研究 | →$15 | 开始承保 | →对等性能 |
| 07/19/2021 | 158.44% | 高盛 | →$36 | 开始承保 | →购买 |
| 07/19/2021 | 57.93% | 加拿大皇家银行资本 | →$22 | 开始承保 | →跑赢大盘 |
| 07/19/2021 | 14.86% | 花旗集团 | →$16 | 开始承保 | →中性 |
| 07/19/2021 | 72.29% | 派珀·桑德勒 | →$24 | 开始承保 | →超重 |
What is the target price for Bright Health Gr (BHG)?
Bright Health Gr(BHG)的目标价格是多少？
The latest price target for Bright Health Gr (NYSE: BHG) was reported by RBC Capital on August 14, 2023. The analyst firm set a price target for $16.00 expecting BHG to rise to within 12 months (a possible 14.86% upside). 10 analyst firms have reported ratings in the last year.
RBC Capital于2023年8月14日报道了Bright Health Gr(纽约证券交易所代码：BHG)的最新目标价。这家分析公司将目标价定为16.00美元，预计必和必拓将在12个月内上涨至14.86%(可能上涨14.86%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Bright Health Gr (BHG)?
分析师对Bright Health Gr(BHG)的最新评级是多少？
The latest analyst rating for Bright Health Gr (NYSE: BHG) was provided by RBC Capital, and Bright Health Gr maintained their sector perform rating.
Bright Health Gr(纽约证券交易所代码：BHG)的最新分析师评级由加拿大皇家银行资本提供，Bright Health Gr维持其行业表现评级。
When is the next analyst rating going to be posted or updated for Bright Health Gr (BHG)?
Bright Health Gr(BHG)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bright Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bright Health Gr was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Bright Health Gr的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Bright Health Gr的上一次评级是在2023年8月14日提交的，所以你应该预计下一次评级将在2024年8月14日左右提供。
Is the Analyst Rating Bright Health Gr (BHG) correct?
分析师对Bright Health Gr(BHG)的评级正确吗？
While ratings are subjective and will change, the latest Bright Health Gr (BHG) rating was a maintained with a price target of $13.00 to $16.00. The current price Bright Health Gr (BHG) is trading at is $13.93, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的光明健康Gr(BHG)评级维持不变，目标价在13.00美元至16.00美元之间。Bright Health Gr(BHG)目前的交易价格为13.93美元，在分析师的预测范围内。